Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 59-8862 in Taxane-Resistant NSCLC
NCT00054314Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Mar 2002
- Primary completion
- Apr 2003
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of ortataxel in non-small cell lung cancer (NSCLC), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Overall Response Rate. Started Mar 2002; status: completed.
02
Drugs
ortataxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00054314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00054314.